• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大量儿童淋巴造血系统恶性肿瘤中p53基因突变分析

Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood.

作者信息

Wada M, Bartram C R, Nakamura H, Hachiya M, Chen D L, Borenstein J, Miller C W, Ludwig L, Hansen-Hagge T E, Ludwig W D

机构信息

Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine 90048.

出版信息

Blood. 1993 Nov 15;82(10):3163-9.

PMID:8219205
Abstract

p53 mutations are found in a wide variety of cancers, including hematologic malignancies. These alterations apparently contribute to development of the malignant phenotype. We analyzed a large series of lymphoid (330 cases) and a smaller series of myeloid (29 cases) malignancies of childhood for p53 mutations by single-strand conformational polymorphism (SSCP) following polymerase chain reaction. Samples with abnormal SSCP were reamplified and analyzed by direct sequencing method. p53 mutations were detected within the known mutational hotspots (exons 5 to 8) in 8 of 330 lymphoid malignancies, and in none of 29 myeloid malignancies, showing that the frequency of p53 mutations in childhood lymphoid malignancies was very low (8 of 330 cases [2%]). Four of these patients had very aggressive, fatal acute lymphocytic leukemia (ALL). None of 13 infants and none of 48 patients with T-lineage leukemia had detectable p53 mutations in their ALL cells. Exceptionally, p53 mutations were comparatively frequent in a small sample of B-cell non-Hodgkin's lymphomas (2 of 8 cases). Mutations were detected in samples from two patients with ALL at relapse; these were not detected in samples at initial diagnosis from the same patients, suggesting that p53 mutations may be associated with progression to a more malignant phenotype. Seven of eight alterations of p53 were missense mutations, and seven of eight samples may be heterozygous for the mutant p53, indicating that p53 protein may act in a dominant negative fashion.

摘要

p53突变存在于多种癌症中,包括血液系统恶性肿瘤。这些改变显然有助于恶性表型的发展。我们通过聚合酶链反应后的单链构象多态性(SSCP)分析了一大系列儿童期淋巴样(330例)和一小系列儿童期髓样(29例)恶性肿瘤中的p53突变。对SSCP异常的样本进行重新扩增,并通过直接测序法进行分析。在330例淋巴样恶性肿瘤中有8例在已知突变热点(外显子5至8)内检测到p53突变,而29例髓样恶性肿瘤中均未检测到,这表明儿童期淋巴样恶性肿瘤中p53突变的频率非常低(330例中的8例[2%])。其中4例患者患有侵袭性很强的致命性急性淋巴细胞白血病(ALL)。13例婴儿和48例T系白血病患者的ALL细胞中均未检测到可检测到的p53突变。例外的是,在一小部分B细胞非霍奇金淋巴瘤样本中(8例中的2例)p53突变相对常见。在两名复发的ALL患者样本中检测到突变;在同一患者的初始诊断样本中未检测到这些突变,这表明p53突变可能与向更恶性表型的进展有关。8例p53改变中有7例为错义突变,8个样本中有7个可能为突变型p53杂合子,这表明p53蛋白可能以显性负性方式起作用。

相似文献

1
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood.大量儿童淋巴造血系统恶性肿瘤中p53基因突变分析
Blood. 1993 Nov 15;82(10):3163-9.
2
Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.血液系统恶性肿瘤中p53突变的检测:免疫细胞化学与DNA分析的比较
Leukemia. 1994 Aug;8(8):1342-9.
3
Mutations of p53 in Wilms' tumors.肾母细胞瘤中p53基因的突变
Mod Pathol. 1995 Jun;8(5):483-7.
4
[Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].[血液系统恶性肿瘤中p53和N-ras基因微小改变的分子研究]
Hokkaido Igaku Zasshi. 1994 May;69(3):543-54.
5
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.儿童T细胞急性淋巴细胞白血病中p53、p21、p16、p15和RAS基因的改变
Leuk Res. 1999 Feb;23(2):115-26. doi: 10.1016/s0145-2126(98)00146-5.
6
Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.儿童t(1;19) - 急性淋巴细胞白血病中p53和ras基因的突变
Blood. 1995 May 1;85(9):2546-52.
7
[Value of protein 53 expression in lymphoma. Its correlation with genetic mutations].[蛋白质53在淋巴瘤中的表达价值。其与基因突变的相关性]
Sangre (Barc). 1997 Oct;42(5):369-75.
8
[p53 and hematologic malignancies].[p53与血液系统恶性肿瘤]
Pathol Biol (Paris). 1997 Dec;45(10):898-908.
9
The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.
Blood. 1990 Apr 15;75(8):1684-90.
10
A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies.B细胞慢性淋巴细胞白血病中独特的p53突变谱,与其他淋巴样恶性肿瘤不同。
Mol Carcinog. 1995 Dec;14(4):227-32. doi: 10.1002/mc.2940140402.

引用本文的文献

1
FLT4 activation promotes acute lymphoid leukemia survival through stabilization of MDM2/MDMX and inactivation of p53.FLT4激活通过稳定MDM2/MDMX和使p53失活来促进急性淋巴细胞白血病的存活。
Oncogenesis. 2025 May 2;14(1):14. doi: 10.1038/s41389-025-00552-7.
2
Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.TP53 基因多态性与摩洛哥儿童急性淋巴细胞白血病风险的关联。
Mol Biol Rep. 2022 Sep;49(9):8291-8300. doi: 10.1007/s11033-022-07643-3. Epub 2022 Jun 15.
3
Expression and Mutational Analysis in Hematological Malignancy in Jeddah, Saudi Arabia.
沙特阿拉伯吉达血液系统恶性肿瘤中的表达及突变分析
Diagnostics (Basel). 2022 Mar 16;12(3):724. doi: 10.3390/diagnostics12030724.
4
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.化疗与错配修复缺陷协同作用促进 TP53 突变和 ALL 复发。
Nat Cancer. 2021 Aug;2(8):819-834. doi: 10.1038/s43018-021-00230-8. Epub 2021 Jul 22.
5
TP53 alterations in relapsed childhood acute lymphoblastic leukemia.复发儿童急性淋巴细胞白血病中的 TP53 改变。
Cancer Sci. 2020 Jan;111(1):229-238. doi: 10.1111/cas.14238. Epub 2019 Dec 5.
6
PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.PHF6 调节造血干/祖细胞,其缺失与 TLX3 的表达协同作用导致白血病。
Blood. 2019 Apr 18;133(16):1729-1741. doi: 10.1182/blood-2018-07-860726. Epub 2019 Feb 12.
7
mutation, alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.突变、改变和髓系抗原表达可预测T细胞急性淋巴细胞白血病首次复发儿童的预后异质性。
Haematologica. 2017 Jul;102(7):e249-e252. doi: 10.3324/haematol.2016.157792. Epub 2017 Mar 30.
8
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.儿科临床前试验计划评估的针对小儿急性淋巴细胞白血病的新药物的综述。
Leukemia. 2016 Nov;30(11):2133-2141. doi: 10.1038/leu.2016.192. Epub 2016 Jul 15.
9
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.新型MDM2抑制剂MK-8242的初始测试(第1阶段)——由儿科临床前测试项目开展
Pediatr Blood Cancer. 2016 Oct;63(10):1744-52. doi: 10.1002/pbc.26064. Epub 2016 May 30.
10
Identifying novel therapeutic agents using xenograft models of pediatric cancer.利用儿科癌症异种移植模型鉴定新型治疗药物。
Cancer Chemother Pharmacol. 2016 Aug;78(2):221-32. doi: 10.1007/s00280-016-3042-6. Epub 2016 May 18.